Dipeptidyl peptidase IV and Mortality After an Acute Heart Failure Episode

• Type: Article in International Scientific Journal
• Date: 2013

Authors

lourenco, p (Author) Other; frioes, f (Author) Other; silva, n (Author) Other; guimaraes, jt (Author) FCNAUP; bettencourt, p (Author) FMUP

Journal

Title: Journal of Cardiovascular Pharmacology

Vol. 62

Pages: 138-142

ISSN: 0160-2446

Publisher: Wolters Kluwer Health

Indexing

ISI Web of Knowledge - 14 Citations

Scopus - 14 Citations

Scientific classification

FOS: Medical and Health sciences > Clinical medicine

Other information

Authenticus ID: P-006-8MV

DOI: 10.1097/fjc.0b013e3182949673

Abstract (EN): Background: Dipeptidyl peptidase IV (DPP IV) is a key enzyme in B-type natriuretic peptide processing. DPP IV was never studied in human heart failure (HF). We aimed to measure DPP IV concentration in acute HF and determine its association with mortality. Methods and Results: Patients hospitalized with acute HF were eligible. We excluded patients with acute coronary syndromes. A discharge blood sample was collected from all patients and they were followed for a 6-month period. Outcome was HF death. Patients were compared across DPP IV quartiles. A Cox regression analysis was used to assess the prognostic power of DPP IV. We studied 164 patients. Median age was 78 years, 48.8% were men, and 63 had type 2 diabetes and 59.1% had left ventricular systolic dysfunction. Quartiles of DPP IV were <215.2; 215.2 and <269.3; 269.3 and <348.6; and 348.6 ng/mL; groups were homogenous between them. Seventeen patients died. Patients with DPP IV in the last quartile had a hazard ratio of HF death up to 6 months of 2.89, 95% confidence interval, 1.11-7.46. Association was B-type natriuretic peptide independent. Conclusions: Discharge DPP IV 348.6 ng/mL conferred an approximately 3-fold higher risk of 6-month HF death. Further studies would be important to understand the role of DPP IV in HF.

Language: English

Type (Professor's evaluation): Scientific

No. of pages: 5